Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Lilly, Roche Drugs Fail to Stymie Inherited Form of Alzheimer's

share with twitter share with LinkedIn share with facebook
share via e-mail
02/10/2020 | 11:13am EDT

By Peter Loftus

In the latest failed attempt to help people with Alzheimer's disease, a study found that experimental drugs from Eli Lilly & Co. and Roche Holdings AG failed to help people with a rare, inherited form of the dementia-causing disease.

The negative outcome continues a long streak of studies in which experimental drugs fail to slow, halt or reverse the underlying worsening of Alzheimer's disease. Current treatments for Alzheimer's only temporarily alleviate symptoms but can't halt the underlying disease.

Some drugmakers including Pfizer Inc. have exited from Alzheimer's research, but much of the industry continues to push ahead, given the growing burden of Alzheimer's. Last year, Biogen Inc. reversed course and said it would pursue regulatory approval for an experimental Alzheimer's drug despite previously finding disappointing results in studies.

Last year, there were 405 drugs being studied for Alzheimer's, up from 381 in 2018 and ranking Alzheimer's behind several types of cancer as top areas of research, according to a report from research firm Informa UK Ltd.

The latest clinical trial, led by researchers at Washington University School of Medicine in St. Louis and funded by the National Institute on Aging, tested the drugs in people with dominantly inherited Alzheimer's disease, which affects less than 1% of the Alzheimer's population.

People confirmed to have the genetic mutations are almost certain to develop Alzheimer's, and it often starts in their 30s to 50s, younger than most Alzheimer's patients. If a person's parent had the mutation, they have a 50-50 chance of inheriting it.

The trial, which started in 2012, tested the ability of the two drugs to slow the worsening of cognitive function in people with the mutations. Patients either had no symptoms or mild dementia at the start of the trial. Some of the 194 participants were given Lilly's solanezumab, others were given Roche's gantenerumab and a third group received a placebo.

Neither drug was able to slow cognitive decline as measured by several tests of thinking and memory, Washington University School of Medicine said Monday.

Lilly's shares fell about 2% and Roche's American depositary receipts were little changed in recent trading Monday.

The Lilly and Roche drugs are designed to work by reducing a sticky substance called beta amyloid that builds up in the brains of Alzheimer's patients.

Lilly and Roche have previously tested their drugs in clinical trials of patients with the more common form of Alzheimer's that typically affects people 65 and older. Lilly's drug failed to significantly help patients and Roche halted two studies of its drug after concluding it wouldn't help.

Lilly said it won't pursue an application for regulatory approval of solanezumab to treat dominantly inherited Alzheimer's. Roche said it is unable to draw firm conclusions about the effect of gantenerumab in inherited Alzheimer's.

Roche and Lilly said their experimental drugs continue to be tested in other clinical trials. Many companies are testing higher doses of their drugs, and at earlier stages of disease than in previous failed trials of the same drugs.

Washington University School of Medicine researchers said they plan to present more detailed analyses of the trial at medical meetings in April and July.

Write to Peter Loftus at peter.loftus@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
BIOGEN INC. 0.08% 316.38 Delayed Quote.6.62%
ELI LILLY AND COMPANY 0.20% 138.72 Delayed Quote.5.55%
INFORMA PLC 4.63% 442.6 Delayed Quote.-48.35%
PFIZER, INC. -0.09% 32.64 Delayed Quote.-16.69%
ROCHE HOLDING AG 1.70% 314.05 Delayed Quote.-5.53%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ELI LILLY AND COMPANY
03/31ELI LILLY AND : Sitryx to Collaborate on Immunometabolic Medicines
DJ
03/31ELI LILLY AND : Lilly's Taltz Receives U.S. FDA Approval for the Treatment of Pe..
AQ
03/31ELI LILLY AND : Lilly and Sitryx Announce Licensing and Research Collaboration t..
PR
03/30ELI LILLY AND : Gets FDA OK for Taltz in Pediatric Plaque Psoriasis
DJ
03/27Coronavirus Upends Testing of New Drugs
DJ
03/25ELI LILLY AND COMPANY : - Updates from Lilly about insulin supply and affordabil..
AQ
03/24ELI LILLY AND COMPANY : - Lilly Provides Update on Clinical Trial Activities dur..
AQ
03/24ELI LILLY AND : AC Immune Receives Second Milestone and New Milestone to Increas..
AQ
03/24ELI LILLY AND : Updates from Lilly about insulin supply and affordability
PR
03/23ELI LILLY AND COMPANY : - Kathryn Beiser to join Lilly as Vice President, Global..
AQ
More news
Financials (USD)
Sales 2020 23 922 M
EBIT 2020 7 308 M
Net income 2020 5 576 M
Debt 2020 10 705 M
Yield 2020 2,13%
P/E ratio 2020 21,6x
P/E ratio 2021 17,4x
EV / Sales2020 5,71x
EV / Sales2021 5,30x
Capitalization 126 B
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 147,44  $
Last Close Price 138,72  $
Spread / Highest target 21,1%
Spread / Average Target 6,28%
Spread / Lowest Target -18,5%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Myles Oneill Senior VP & President-Manufacturing Operations
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY5.55%125 824
JOHNSON & JOHNSON-8.82%350 661
ROCHE HOLDING AG-5.53%273 496
MERCK & CO., INC-15.40%195 166
NOVARTIS-17.30%183 669
PFIZER, INC.-16.69%181 241